1-Methyl-1H-benzimidazol-6-amine → [7-(6-Methoxy-pyridin-3-yl)-pyrrolo[2,1-f][1,2,4]triazin-2-yl]-(3-methyl-3H-benzimidazol-5-yl)-amine

HRID 1262369

反応式

HRID 1262369 の反応式
CS([C:4]1[N:9]=[CH:8][C:7]2=[CH:10][CH:11]=[C:12]([C:13]3[CH:14]=[N:15][C:16]([O:19][CH3:20])=[CH:17][CH:18]=3)[N:6]2[N:5]=1)=O.[CH3:21][N:22]1[C:26]2[CH:27]=[C:28]([NH2:31])[CH:29]=[CH:30][C:25]=2[N:24]=[CH:23]1>>[CH3:20][O:19][C:16]1[N:15]=[CH:14][C:13]([C:12]2[N:6]3[C:7]([CH:8]=[N:9][C:4]([NH:31][C:28]4[CH:29]=[CH:30][C:25]5[N:24]=[CH:23][N:22]([CH3:21])[C:26]=5[CH:27]=4)=[N:5]3)=[CH:10][CH:11]=2)=[CH:18][CH:17]=1

参加物

3

実験手順

Following the synthetic and purification procedures described in Example 1293d, 2-methanesulfinyl-7-(6-methoxy-pyridin-3-yl)-pyrrolo[2,1-f][1,2,4]triazine (60 mg, 0.2 mmol) was coupled to 3-methyl-3H-benzimidazol-5-ylamine (53 mg, 0.36 mmol) at 105° C. for 86 h to afford the title compound. Yield of TFA salt: 33 mg (34%) of brown powder. LC/MS: 372 (M+H); HPLC: 95% pure, RT=2.29 min; 1H NMR: (DMSO, δ) 10.04 (s, 1H), 9.34 (s, 1H), 9.22 (d, J=2.0, 1H), 9.06 (s, 1H), 8.51 (s, 1H), 8.35 (dd, J=8.9, 2.4, 1H), 7.79 (d, J=9.0, 1H), 7.64 (dd, J=9.0, 1.4, 1H), 7.24 (d, J=4.9, 1H), 7.05 (s, 1H), 7.03 (d, J=4.9, 1H), 4.06 (s, 3H), 3.95 (s, 3H).

後処理

  1. custompurification procedures

出典と根拠

ORDレコード
ord-a8aa820c444b47eba63b0bfdbbb33902
出典データセット
uspto-grants-2013_06
特許番号
US08471005B2

関連ノート

読み込み中…